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Maintaining genomic integrity is of paramount im-
portance to embryonic stem cells (ESCs), as muta-
tions are readily propagated to daughter cells.
ESCs display hypersensitivity to DNA damage-
induced apoptosis (DIA) to prevent such propaga-
tion, although the molecular mechanisms underlying
this apoptotic response are unclear. Here, we report
that the regulatory RNA Apela positively regulates
p53-mediated DIA. Apela is highly expressed in
mouse ESCs and is repressed by p53 activation,
and Apela depletion compromises p53-dependent
DIA. Although Apela contains a coding region, this
coding ability is dispensable for Apela’s role in p53-
mediated DIA. Instead, Apela functions as a regula-
tory RNA and interacts with hnRNPL, which prevents
the mitochondrial localization and activation of p53.
Together, these results describe a tri-element nega-
tive feedback loop composed of p53, Apela, and
hnRNPL that regulates p53-mediated DIA, and they
further demonstrate that regulatory RNAs add a layer
of complexity to the apoptotic response of ESCs
after DNA damage.
INTRODUCTION
Embryonic stem cells (ESCs) have a unique surveillance system
for maintaining genome stability. Compared to differentiated
cells, ESCs easily undergo apoptosis and differentiation upon
DNA damage (Hong and Stambrook, 2004; Liu et al., 2013),
which probably minimizes the risk of genome instability because
it removes cells with damaged DNA from the population and en-ables a population with low DNA mutation burden (Cervantes
et al., 2002). Indeed, the mutation frequency of the ESC popula-
tion is about 100 times lower than that of differentiated cells (Cer-
vantes et al., 2002). We and others have previously shown that
p53 plays important roles in promoting the differentiation of
mouse ESCs (mESCs) by repressing Nanog and other master
regulators (Li et al., 2012; Lin et al., 2005). However, our under-
standing of the roles of p53 in DNA damage-induced apoptosis
(DIA) of ESCs is incomplete, mainly because the mechanisms
and the in vivo support are lacking. On the one hand, p53 is
not required for the self-renewal of mESCs since mouse em-
bryos with p53 knockout bypass the ESC stage (Donehower
et al., 1992). On the other hand, p53 may have a pro-apoptotic
function in mESCs based on a recent in vivo study showing
that activated p53 is capable of regulating apoptotic genes in
blastocysts (Goh et al., 2012). Given that mESCs have their
unique transcriptional program and epigenome (Young, 2011),
it is possible that the p53 signaling pathway regulates DNA dam-
age-induced apoptosis (DIA) of ESCs by using part of the ESC-
specific transcriptome. Therefore, identifying the ESC-specific
part of the p53 transcriptional program will provide insights
into how p53 regulates DIA of mESCs.
The observation that p53 activates Puma, a pro-apoptotic
gene, in blastocysts leads us to investigate whether p53 regulates
DIA of mESCs (Goh et al., 2012). After establishing that p53 is
required for DIA of mESCs, we employ an integrative genome-
wide approach to identify p53 targets that maymediate p53 func-
tion in DIA of mESCs. We focus on Apela (Apelin receptor early
endogenous ligand) that encodes a putative peptide and find
that Apela is involved in p53-mediated DIA of mESCs. Unexpect-
edly, the coding ability of Apela is dispensable for its pro-
apoptotic function in mESCs. We further show that Apela acts
as a regulatory RNA that modulates p53 activity by interacting
with heterogeneous nuclear ribonucleoprotein L (hnRNPL), an
inhibitory regulator of p53. Our results reveal a regulatory RNA-
mediated negative feedback loop that regulates p53-mediatedCell Stem Cell 16, 669–683, June 4, 2015 ª2015 Elsevier Inc. 669
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Figure 1. Apela Is Repressed by p53 and Enriched in mESCs
(A) Left, Annexin V staining to measure the percentage of apoptotic cells. Right, the percentage of survived cells treated with different concentrations of ADR for
24 hr. Error bars are SEM; n = 3.
(B) Western blot (W.B.) of mESCs treated with 0.5 mM ADR for various times (upper panels) and with various concentrations of ADR for 24 hr (lower panels).
(C) Identifying mESC-enriched p53 direct targets upon DNA damage.
(legend continued on next page)
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DIA of mESCs, and they demonstrate that regulatory RNAs are
part of p53 signaling in mESCs.
RESULTS
p53 Regulates DIA of mESCs
To test whether DIA of mESCs is p53 dependent, we first
measured the kinetics of apoptosis in p53+/+ and p53/mESCs
in response to DNA damage using Annexin V staining (Figure 1A,
left panel, and Figure S1A). We found that p53 plays a prominent
role in regulating DIA of ESCs: around 80% of p53+/+ mESCs
became apoptotic 36 hr after receiving treatment with 0.5 mM
Adriamycin (ADR) while less than 5% of p53/ mESCs were
apoptotic (Figure 1A, left panel, and Figure S1A). To rule out
the dose-specific effect, we treated both p53+/+ and p53/
mESCs with different doses of ADR for 24 hr and observed
p53-dependent DIA at all the tested doses (Figure 1A, right
panel). However, the difference in the percentage of apoptotic
cells between p53+/+ and p53/ mESCs is dependent on the
dose of ADR (Figure 1A). Using cleaved caspase-3 as another
apoptosis marker, we confirmed that p53 regulates DIA of
mESCs, and apoptosis increased as early as 8 hr after DNA dam-
age (Figure 1B). Our previous study showed that p53+/+ and
p53/ mESCs have similar cell cycle profiles before and after
ADR treatment (Li et al., 2012), excluding the contribution of
cell cycle arrest to p53-mediated DIA of mESCs.
Apela Is Repressed by p53 and Is Highly Expressed in
mESCs
We attempted to identify p53 downstream targets that may be
involved in p53-mediated DIA of mESCs. For this, we used a
genome-wide approach by integrating RNA-seq and ChIP-seq
(Li et al., 2012) (Figure 1C). Using RNA-seq data from p53+/+
and p53/ mESCs that were either untreated or treated with
ADR, we identified 266 upregulated and 42 downregulated
p53-dependent transcripts in response to DNA damage (Fig-
ure 1C and Table S1). After integrating this with p53 ChIP-seq
data, we cataloged 259 upregulated and 32 downregulated
p53 direct targets (Figure 1C), which were defined as transcripts
with expression change in a p53-dependent manner and associ-
ated with at least one p53 binding site (Table S1). Among the en-
riched pathways in these targets, regulation of cell death (p =
0.0031), apoptosis (p = 0.0088), and programmed cell death
(p = 0.0092) pathways are relevant to the apoptotic function of
p53 in mESCs (Table S1). Targets enriched in mESCs are more
likely to modulate p53’s mESC-specific function. Therefore, we
excluded cell-type-nonspecific p53 targets by comparing the
expression levels of all transcripts in mESCs to those in mouse
embryonic fibroblasts (MEFs) (Figure 1C, also see Supplemental
Experimental Procedures). This analysis resulted in 130 p53-
activated and 22 p53-repressed transcripts that are enriched in
mESCs (Table S1 and Table S2). We were interested in p53-(D) Real-time PCR tomeasure the levels ofApela andNanog (control). Ctr, untreate
n = 3. t test; *p < 0.05; **p < 0.01.
(E) Upper, northern blot with total RNA; lower, real-time PCR. Error bars are SEM
(F) RNA-seq and ChIP-seq on the Apela locus. Black bars underneath the p53 (Ad
annotated using histone modifications, Med1, and Pol II.
See also Figure S1, Table S1, and Table S2.repressed transcripts because p53-repressed transcripts are
more likely to play ESC-specific functions than p53-activated
transcripts and their regulation is relatively less well understood
(Li et al., 2012; Zhang et al., 2013). Among the 22 p53-repressed,
ESC-enriched transcripts, several transcripts, such as Snora15,
Dnmt3b, Prdm14, Lef1, Foxd3, Notch4, Cdk6, and Hmga1, have
been shown to play critical roles in the regulation of self-renewal
and differentiation of ESCs (Table S2). We decided to focus on
Apela (also called Gm10664), which had been annotated as a
long non-coding RNA in the NCBI database. However, its zebra-
fish homolog has recently been shown to encode a secretory
peptide called Toddler (Pauli et al., 2014) or ELABELA (Chng
et al., 2013), which regulates cell movement during gastrulation.
Hereinafter, we use the latest official name in NCBI, Apela, to
refer to this RNA species. Because our previous study had
shown that p53 has a non-cell-autonomous function in mESCs
(Lee et al., 2010), our initial impression was that we had discov-
ered a secretory signaling peptide, Apela, which is part of the
cell-non-autonomous function of p53 in mESCs.
Using real-time PCR, we validated that Apela was repressed
by DNA damage in a p53-dependent manner (Figure 1D and Fig-
ure S1B). In addition, in the absence of extrinsic stress, the
amount of Apela was significantly higher in p53/ mESCs
than in p53+/+ mESCs (Figure 1D, compare blue bars in the left
panel), suggesting that p53 actively represses Apela even
without extrinsic DNA damage. Both northern blot and real-
time PCR verified that Apela was highly expressed in mESCs
but not in neural progenitor cells (NPCs) and MEFs (Figure 1E).
Specifically, the levels of Apela were about 100 times higher in
mESCs than in NPCs or MEFs (Figure 1E). The expression levels
of Apela were less than those of Pou5f1 (also called Oct4) and
Nanog mRNAs but were comparable to those of Tfcp2l1 and
Klf4 mRNAs, which also encode ESC transcription factors (Fig-
ure S1C) (Chen et al., 2008). Northern blot analysis and
shRNA-mediated knockdown demonstrated that Apela had
only one splicing variant in mESCs and the size of Apela in
mESCs was the same as that of in vitro transcribed Apela (Fig-
ures S1D and S1E).
p53 Binds to the Enhancer Region of the Apela Locus
Next, we inspected our mRNA-seq and public RNA-seq data
and found that Apela is spliced in mESCs as annotated in
NCBI (Figure 1F and Figure S1F). Using ChIP-seq datasets of
RNA polymerase II (Pol II), mediator (Med1), and epigenetic
marks, we depicted a precise transcriptional unit, including
the enhancer domain, the promoter, and the gene body, for
Apela gene (Figure 1F). H3K4me3 marks the promoter while
H3K79me2 marks the gene body (Berger, 2007; Heintzman
et al., 2007; Rahl et al., 2010). H3K4me1, H3K27ac, Med1,
and p300 together indicated that the Apela gene has a distal
enhancer domain in mESCs (Figure 1F) (Berger, 2007; Heintz-
man et al., 2007; Kagey et al., 2010). p53 did not bind to thed; Adr, treatedwith 0.5 mMADR for 8 hr. A.U., arbitrary unit. Error bars are SEM;
; n = 3.
r) view are identified p53 peaks; R1-3, Region 1–3. Promoter and enhancer are
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promoter of Apela. Instead, it had three binding regions (R1–3)
within the enhancer domain of the Apela gene (Figure 1F),
which is consistent with our previous finding that enhancer
interference is one of the mechanisms of p53-mediated tran-
scriptional repression in mESCs upon DNA damage (Li et al.,
2012). The weak binding region (R1) overlapped with the
strong signal of Med1, H3K4me1, H3K27ac, p300, Pol II, and
H3K4me3 while the medium binding region (R2) overlapped
with the weak signal of Med1, H3K4me1, H3K27ac, p300,
and Pol II, suggesting a reverse correlation of the signals of
p53 and the enhancer markers (also see Supplemental Informa-
tion). This annotated enhancer domain was also bound by
many master transcription factors of mESCs, such as Nanog,
Sox2, Oct4, etc. (Figure S1G).
Apela Acts as a Regulatory RNA for p53-Mediated DIA of
mESCs Independent of Its Coding Ability
Because Apela is ESC enriched, we first examined whether
Apela affects the self-renewal of mESCs. Knockdown of Apela
had no detectable effect on the self-renewal of mESCs based
on immunofluorescence staining and immunoblotting of key
transcription factors, mESC proliferation, and colony formation
(Figure 2A, Figures S2A–S2D). Microarray analysis did not iden-
tify anymaster regulators of mESCs or lineagemarkers that were
regulated by Apela knockdown (Table S3). However, during
embryoid body (EB) formation, in which the three germ layers
form, Apela knockdown reduced the mesoderm markers (Flk1
and alpha-actin) and endoderm markers (Foxa2 and Gata4),
but not the ectoderm markers (Figure S2E). This result is consis-
tent with the studies in zebrafish showing that Apela regulates
mesoderm and endoderm development (Chng et al., 2013; Pauli
et al., 2014). Therefore, Apela does not affect mESCs under un-
differentiated conditions.
We then reasoned that Apela may be involved in a p53-medi-
ated stress response of mESCs since Apela is repressed by p53.
To test this, we examined the response of mESCs with Apela
knockdown to DNA damage. Both Annexin V staining and immu-
noblotting of cleaved caspase-3 showed that the reduction of
Apela decreased DIA of mESCs in a p53-dependent manner
(Figures 2B, 2C, and 2D). Thus, Apela is involved in p53-medi-
ated DIA of mESCs. We then tested whether Apela regulates
the transcription of p53-regulated apoptotic genes. We did not
observe any consistent effect of Apela knockdown on the
expression of Cdkn1a (p21), Mdm2, Bcc3 (Puma), Btg2, and
Bax in both untreated and ADR-treated mESCs (Figure S3A).
Recently, p53 has been shown to regulate DIA in ESCs through
its non-transcriptional role in mitochondria (Han et al., 2008; Liu
et al., 2013). We therefore tested whether Apela regulates the
non-transcriptional function of p53. For this, we first isolated
cytoplasmic and nuclear fractions from ESCs and found that
Apela knockdown decreased the cytoplasmic fraction, but not
the total amount, of p53 under DNA damage (Figure 2E). Further,
we isolated the mitochondrial fraction and observed that Apela
knockdown decreased the amount of p53 in the mitochondria
of mESCs (Figure 2F), suggesting that Apela regulates p53-
mediated apoptosis in mESCs by altering its mitochondrial
localization.
After establishing the role of Apela in p53-dependent DIA of
mESCs, we wanted to gain insights into the underlying mecha-672 Cell Stem Cell 16, 669–683, June 4, 2015 ª2015 Elsevier Inc.nism. In zebrafish, Apela is a short, secretory peptide and acts
as a mitogen through the G protein-coupled Apelin receptor
(Aplnr) during gastrulation (Chng et al., 2013; Pauli et al., 2014).
Thus, one possibility is that Apela regulates DIA of mESCs
through the Apela/Aplnr axis, a mechanism similar to our previ-
ously discovered non-cell-autonomous axis of p53/Wnt/Wnt re-
ceptor in mESCs (Lee et al., 2010). For this, we planned to knock
down Aplnr to examine whether Aplnr knockdown phenocopies
Apela knockdown. Surprisingly, we found that Aplnr is not ex-
pressed in mESCs based on RNA-seq analysis in the absence
or presence of DNA damage (Figure 3A). As a control, its neigh-
boring gene, Tnks1bp1, is expressed (Figure 3A). ChIP-seq data
showed that the Aplnr locus was blanketed with a repressive his-
tone modification, H3K27me3, and essentially had no active
marks, H3K4me3, and H3K79me2 (Figure 3A). RNA Pol II was
absent from the locus, firmly demonstrating thatAplnr is silenced
in mESCs. To investigate the expression pattern of Aplnr during
early developmental events, we measured the levels of Aplnr
mRNA during EB formation (Figure 3B). At the ESC stage
(0 day EB), there was no expression of Aplnr mRNA (Figure 3B),
confirming the result from RNA-seq (Figure 3A). Notably, the
expression of AplnrmRNA gradually increased during differenti-
ation (Figure 3B). In contrast, the levels of Apela increased about
2-fold from day 0 to day 8 (Figure 3C). These results show that
Aplnr, the gene encoding the receptor for Apela, is completely
silenced in mESCs but is expressed upon the differentiation of
mESCs, explaining the observation that Apela knockdown regu-
lated the expression of mesoderm and endoderm markers dur-
ing EB formation (Figure S2E). Therefore, in mESCs, Apela has
an Aplnr-independent function.
There are two possible explanations for the Aplnr-independent
role of Apela. One is that the Apela peptide has another uniden-
tified receptor that mediates Apela’s function in regulating DIA of
mESCs. We carried out BLASTp (Basic Local Alignment Search
Tool-protein) search and did not find any protein that has a
similar amino acid sequence to that of Aplnr, therefore arguing
against the existence of another receptor of Apela peptide with
a similar amino acid sequence. The other possibility is that the
Apela RNA acts as a regulatory RNA to regulate p53-mediated
DIA in mESCs that is independent of its coding ability and recep-
tor Aplnr. Apela has a putative coding region (235–399 nucleo-
tides [nts]). Within this putative coding region, there are two start
codons (Figure 3D). To test the second possibility, we disrupted
the putative translation of Apela RNA by introducing different
modifications to Apela: (1) changing the first start codon of Apela
from ATG to GGG (Apela_noATG); (2) changing both start co-
dons from ATG to GGG (Apela_2noATG); and (3) deleting the
whole putative coding region of Apela (Apela_Dcoding) (Fig-
ure 3D). We then performed rescue experiments using these
different versions of modified Apela to test whether Apela
without the putative coding ability can rescue the decreased
apoptosis caused by Apela knockdown (Figures 3E and 3F
and Figure S3B). Importantly, both wild-type Apela (Apela_WT)
and modified Apela rescued the phenotype of Apela knockdown
(Figure 3F and Figure S3B), demonstrating that the coding ability
of Apela is dispensable for its function in regulating DIA of
mESCs. These results together demonstrate that Apela acts as
a regulatory RNA to regulate p53-mediated DIA of mESCs
even though it has a coding capacity.
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Figure 2. Apela Is Involved in p53-mediated DIA of mESCs
(A) Real-time PCR showing Apela knockdown. Error bars are SEM; n = 3. t test; *p < 0.05; **p < 0.01.
(B) Histograms of the Annexin V staining of mESCs in the presence (shApela_1 and shApela_2) or absence (shLuc) of Apela knockdown. Ctr, untreated; Adr,
treated with 0.5 uM ADR for 24 hr.
(C) Quantification of (B). Error bars are SEM; n = 3. t test; *p < 0.05; **p < 0.01.
(D) W.B. of cleaved caspase-3, p53, and b-actin.
(E) W.B. showing the effect of Apela knockdown on the sub-cellular localization of p53. Each lane of cytoplasmic and nuclear fractions was loaded with proteins
from same number of cells. GAPDH, a cytoplasmic marker; H3, a nuclear marker.
(F) W.B. showing the effect of Apela knockdown on the sub-cellular localization of p53. TFP1, a mitochondrial marker; a-tubulin, a cytosolic marker; Lamin A/C, a
nuclear marker. Each lane of mitochondrial and cytosolic fractions contains the same amount of protein.
See also Figure S2 and Table S3.To test whether Apela peptide, if produced, has a role in DIA of
mESCs, we performed the rescue experiments using synthe-
sized Apela peptide (Figure 3G). We did not observe any rescue
effect of the Apela peptide at a wide range (1–1,000 ng/ml), sug-
gesting that the mature Apela peptide, if produced, has no func-
tion in p53-mediated DIA of mESCs.Apela Interacts with hnRNPL
Since some regulatory RNAs function through their binding part-
ners (Huarte et al., 2010; Klattenhoff et al., 2013; Rinn et al.,
2007), we chose to gain further insights into the role of Apela in
p53-mediated DIA of ESCs by using an RNA pull-down assay
(RPA) to identify the protein or proteins that bind to Apela.Cell Stem Cell 16, 669–683, June 4, 2015 ª2015 Elsevier Inc. 673
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Figure 3. The Coding Ability of Apela Is Dispensable for Its Function in p53-Mediated DIA of mESCs
(A) RNA-seq and ChIP-seq of histone modifications and RNA Pol II on the Aplnr locus.
(B andC) Real-time PCRmeasuring the expression ofAplnr (B) andApela (C) during EB formation. 0 day, themESC stage; non-RT, no reverse transcriptase. Error
bars are SEM; n = 3.
(D) Schematics showingmodifications of the coding region of Apela: Apela_WT, wild-type Apela; Apela_nonATG, Apelawith the first start codon ATG changed to
GGG; Apela_2noATG, Apela with both start codons changed to GGG; Apela_Dcoding, Apela without the coding region.
(E) Real-time PCR measuring the relative RNA level of Apela in the rescue experiments: empty vector and vectors expressing modified Apela were stably
transduced into mESCs containing shLuc, shApela_1, and shApela_2 using a PiggyBac system. Error bars are SEM; n = 3. t test; *p < 0.05; **p < 0.01.
(F) Rescue experiment: Annexin V staining of mESCs (shLuc, shApela_1, and shApela_2) transduced with the empty vector or a vector expressing an Apela
variant (Apela_noATG, Apela_2noATG, or Apela_Dcoding). Error bars are SEM; n = 3. t test; *p < 0.05; **p < 0.01.
(G) Effect of Apela peptide (1–1,000 ng/ml) on DIA of mESCs. Error bars are SEM; n = 3. t test; *p < 0.05; **p < 0.01; n.s., not significant.
See also Figure S3.
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Figure 4. Apela Binds to hnRNPL Independent of p53 Status and DNA Damage
(A) Silver staining of RPA. Right, representative peptides identified by mass spectrometry.
(B) W.B. showing RPA from (A) with hnRNPL antibody (Ab), hnRNPK Ab (control), and Lin28 Ab (control). Ab1, first Ab for hnRNPL.
(C) W.B. showing RPA using Apela and two other RNA controls, NR_045496 and Snhg1. Ab2, another Ab for hnRNPL.
(D) RIP-seq showing average-normalized, log2-transformed FPKM of hnRNPL-RIP and Input. The two red lines are the arbitrary cutoffs of 8-fold enrichment.
(legend continued on next page)
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We first used a candidate approach to examine whether Apela
binds to several ESC master regulators, such as Oct4, Nanog,
Sox2, Klf4, and Utf1 (Figure S4A), and chromatin binding pro-
teins, such as Suz12, Gcnf, G9a, and Dnmt3b (Figure S4B). We
neither observed any enrichment of these proteins in Apela
RPA as compared to anti-sense Apela RPA (control) (Figures
S4A and S4B) nor found any evidence that Apela binds to the
p53 protein (Figure S4B). Thus, this candidate approach did
not identify any protein that binds Apela. Next, we employed
an unbiased approach, which combines RPA with silver staining
followed by mass spectrometry (Figure 4A) (Rinn et al., 2007;
Tsai et al., 2010). This approach revealed that Apela pulled
down two bands, which represented the same protein, hnRNPL
(Figures 4A and S4C). Both hnRNPL splicing variants were en-
riched to a similar degree (Figures 4B and 4C).
We confirmed the interaction between Apela and hnRNPL us-
ing RPA followed by immunoblotting with two different anti-
bodies (Ab1 and Ab2) recognizing hnRNPL (Figures 4B and
4C). Two lines of evidence suggest that the interaction between
Apela and hnRNPL is specific. First, two other RNA binding pro-
teins, hnRNPK and Lin28, did not show enrichment in Apela pull-
down (Figure 4B). Second, two other RNAs, NR_045496 and
Snhg1, did not bind to hnRNPL (Figure 4C).
To verify the interaction reciprocally, we carried out RNA
immunoprecipitation (RIP) and sequencing (RIP-seq) in p53+/+
mESCs (Figures 4D and 4E). 405 transcripts were identified as
hnRNPL-bound when using an 8-fold increase as a cutoff (Fig-
ure 4E and Table S4). Apela was enriched about 48 times in
the immunoprecipitated complex while controls, such asNanog,
Sox2, and Oct4 mRNA, were not enriched (Figures 4D and 4E).
RIP-seq results were confirmed by RIP followed by real-time
PCR (Figure 4F). hnRNPL Ab enriched Apela around 100-fold
compared to enrichment levels of IgG control (Figure 4F). More-
over, the relative enrichment (percentage of input) was not
affected by DNA damage (Figure S4C and Figure 4F, compare
Ctr to Adr) and was independent of the p53 status (Figure S4C
and Figure 4F, compare p53+/+ to p53/). In contrast, the inter-
action between hnRNPL and a control RNA, NR_045496, was
weak. The interaction between hnRNPL and Snhg1, Nanog, or
Oct4 mRNAs was similar to background (IgG). Using recombi-
nant hnRNPL and in vitro transcribedApela, we detected a direct
interaction between hnRNPL and Apela (Figure S4D). In sum-
mary, hnRNPL is a bona fide binding partner of Apela.
hnRNPL contains four RNA recognition motifs (RRM1–4) (Fig-
ure 4G, upper panel). To map the region or regions within
hnRNPL that contribute to Apela binding, we tested the binding
of Apela and anti-sense Apela (as a negative control) to a variety
of hnRNPL truncation variants. The first three RRMs of hnRNPL
were required for Apela binding (Figure 4G). Interestingly, the
fourth RRM was not required for Apela binding. Instead, it deter-
mined the binding specificity since RRM1/2/3 of hnRNPL bound
to anti-sense Apela as well.(E) RIP-seq showing the enrichment of Apela in RIP with hnRNPL Ab. Nanog mR
hnRNPL-RIP were scaled to the same level.
(F) RIP with hnRNPL Ab followed by real-time PCR. Percentage of input was calcu
are SEM; n = 3. t test; *p < 0.05; **p < 0.01; n.s., not significant.
(G) Upper, schematics of hnRNPL variants; lower, RPA using Apela (anti-sense a
See also Figure S4 and Table S4.
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p53 RIP assay (Figure S4E). p53 IP did not pull down Apela,
consistent with the result of RPA (Figure S4B). Because alterna-
tive RNA splicing is one of themajor functions of hnRNPL (Motta-
Mena et al., 2010), we investigated the effect of hnRNPL knock-
down on Apela splicing and sub-cellular localization. hnRNPL
did not affect Apela splicing but slightly altered the sub-cellular
localization of Apela (Figures S4F–S4J).
The 30 UTR of Apela Interacts with hnRNPL and Is
Required for Apela’s Role in p53-mediated DIA of
mESCs
To map the region or regions within Apela that interact with
hnRNPL, we performed RPA using different fragments of Apela
(Figure 5A). A region (732–974 nt) within the 30 UTR (400–974
nt) of Apela bound to hnRNPL as efficiently as the full length of
Apela (Figure 5A). Further mapping of this region (732–974 nt)
indicated that a domain within 793–859 nt was required for the
interaction (Figure 5B). Since the region binding to hnRNPL falls
into the 30 UTR, we then asked whether the 30 UTR of Apela has a
function similar to that of the wild-type in DIA of mESCs. For this,
we performed RPA (Figure 5C) and the rescue experiment (Fig-
ures 5D and 5E) using the 30 UTR and the full length of Apela.
The 30 UTRofApela bound to hnRNPL and rescued the reduction
of DIA as efficiently as wild-type Apela (Apela_WT) (Figures 5D
and 5E), further corroborating the conclusion that the coding
ability of Apela is dispensable for its function in DIA of mESCs
(Figure 3). RPA showed that the 30 UTR ofApela does not interact
with the ribosomal proteins Rpl26 and Rps3 (Figures S5A and
S5B), ruling out the possibility thatApela regulates DIA ofmESCs
by interfering with translation in general.
The Interaction between Apela and hnRNPL Is Required
for Apela’s Role in p53-mediated DIA
Because hnRNPL has been shown to bind to the CA tracts in the
intronic regions of other genes (Hui et al., 2005), we searched the
732–974 nt domain and found that two CA tracts are around this
domain (Figure S5C). RNA secondary structure prediction re-
vealed that these two CA tracts were brought to proximity by a
loop (Figure S5C). These results suggest that these twoCA tracts
are the sites interacting with hnRNPL. To test this, we generated
Apela mutants containing GU substitutions at the first (Ape-
la_M1), second (Apela_M2), or both CA (Apela_M12) tracts and
performed RPA (Figures 5F and 5G). We found that both CA
tracts were involved in the interaction with hnRNPL, and the sec-
ond CA tract was dominant (Figure 5G). Substitution of both CA
tracts with GU tracts completely disrupted the binding between
hnRNPL and Apela (Figure 5G, compare Apela_M12 to anti-
sense). Therefore, hnRNPL binds to Apela only at these two
CA tracts.
To investigate the functional relevance of the interaction
between Apela and hnRNPL to p53-mediated apoptosis inNA, a negative control; green, untreated; red, 0.5 mM ADR for 8 hr. Input and
lated tomeasure the relative interaction between hnRNPL and RNAs. Error bars
nd sense) and Flag-tagged hnRNPL fragments.
A B
C
D E
F G
H I
Figure 5. hnRNPL Binds to the CA Tracts within the 30 UTR of Apela
(A) RPA using different fragments of Apela to map the interacting domain in Apela with hnRNPL. Numbers are the nucleotide positions from 50 and 30 end. Error
bars are SEM; n = 3.
(B) Mapping the region within Apela that binds hnRNPL.
(C) RPA using wild-type Apela (Apela_WT) and the 30 UTR of Apela (Apela_3UTR).
(legend continued on next page)
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mESCs, we performed rescue experiments using wild-type
Apela (Apela_WT) and the Apela mutant containing two CA-to-
GU substitutions (Apela_M12), which disrupted the interaction
between Apela and hnRNPL. Apela_M12 did not rescue the
decreased apoptosis caused by Apela knockdown (Figures 5H
and 5I and Figure S5D), demonstrating that the binding between
hnRNPL and Apela is required for the function of Apela in DIA of
mESCs.
hnRNPL Inhibits p53 Activation and Mitochondrial
Localization in mESCs
To investigate whether hnRNPL is involved in p53-mediated DIA
of mESCs, we used shRNAs to reduce the levels of hnRNPL in
both p53+/+ and p53/mESCs (Figure 6A). hnRNPL knockdown
activated p53 in the absence or presence of ADR treatment (Fig-
ure 6B), indicating that hnRNPL inhibits p53 activation. hnRNPL
knockdown did not increase DNA damage in mESCs as judged
byH2AX-S139P (Figure 6B), suggesting that the increased p53 is
not caused by DNA damage. The activation of p53 coincided
with the increase of p53K379ac, but not p53S18P (Figure 6C).
Since acetylation blocks the degradation of p53 (Kruse and
Gu, 2009), we tested whether hnRNPL knockdown affects the
degradation of p53. Cycloheximide (CHX) was used to inhibit
the translation of p53 in untreated control and hnRNPL knock-
down mESCs and p53 half-life was measured (Figure 6D). We
found that hnRNPL knockdown prolonged the half-life of p53
from about 18 to 33–40 min, demonstrating that hnRNPL knock-
down inhibits the degradation of p53 in mESCs. We were unable
to precisely quantify the effect of hnRNPL knockdown on p53
half-life in ADR-treated mESCs due to rapid cell death induced
by the combinatory treatment of ADR and CHX (Figure S6A).
We found that hnRNPL knockdown increased the mitochondrial
localization (Figure 6E) in addition to the stability of p53 (Fig-
ure 6B). Therefore, hnRNPL has a wider role than Apela in regu-
lating p53 in mESCs: hnRNPL regulates both stability and
mitochondrial localization of p53 while Apela only affects mito-
chondrial localization.
To examine the functional consequence of the increased p53
levels in response to hnRNPL knockdown, we performed An-
nexin V staining and found that hnRNPL knockdown significantly
increased apoptosis in p53+/+, but not p53/, mESCs (Figures
6F and 6G). Thus, hnRNPL prevents mESCs from apoptosis by
inhibiting p53 activation. Since both Apela and hnRNPL are
involved in p53-mediated apoptosis in mESCs and since they
bind to each other, we aimed to dissect the hierarchy of these
two binding partners in p53-mediated apoptosis. To achieve
this, we performed the Annexin V staining of mESCs with the
combinatory knockdown of Apela and hnRNPL. We reasoned
that if hnRNPL is upstream of Apela, the combinatory knock-
down of Apela and hnRNPL would produce results similar to(D) Representative histograms of Annexin V staining of mESCs in the rescue exp
presence (Adr, 24 hr) of ADR treatment.
(E) Quantification of (D). Error bars are SEM; n = 3. t test; *p < 0.05; **p < 0.01.
(F) Sequences of wild-type (WT) Apela and mutants (M1, first CA tract disrupted
(G) RPA using WT and mutant Apela.
(H) Representative histograms of Annexin V staining of mESCs in the rescue exp
(I) Quantification of (H). Error bars are SEM; nR 3. t test; *p < 0.05; **p < 0.01; n
See also Figure S5.
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the combinatory knockdown will have an outcome similar to
that of hnRNPL knockdown. Our results supported the latter
possibility that Apela affects p53-mediated DIA in mESCs up-
stream of hnRNPL (Figures S6B and S6C).
Apela Negatively Regulates the Interaction between
hnRNPL and p53
Previous studies showed that hnRNPK, another member in the
hnRNP family, binds to p53 (Moumen et al., 2005). Thus, we hy-
pothesized that hnRNPL binds to p53. To test this hypothesis,
we performed double immunostaining followed by confocal
analysis and observed a strong co-localization between p53
and hnRNPL in mESCs in the absence or in the presence of
ADR treatment (Figure 7A and Figures S7A and S7B). The co-
localization of hnRNPL and p53 suggests that they bind to
each other in mESCs. To test this, we carried out co-immuno-
precipitation (co-IP) in mESCs using p53 Ab followed by
immunoblotting with hnRNPL Ab and detected an interaction
between p53 and hnRNPL (Figure 7B). DNA damage did not
obviously alter hnRNPL protein levels but increased p53 protein
levels in mESCs (Figure 7B). Despite the fact that more p53 ex-
isted in mESCs after DNA damage, the absolute amount of
hnRNPL in the p53 immuno-complex did not change, suggest-
ing that the relative portion of p53 interacting with hnRNPL
decreases after DNA damage. We also performed co-IP with
recombinant hnRNPL and recombinant p53 and observed a
direct interaction between hnRNPL and p53 (Figure 7C). To
identify the region or regions within p53 that are responsible
for the interaction with hnRNPL, we generated recombinant
p53 containing the amino terminal domain (ATD), DNA binding
domain (DBD), or carboxyl terminal domain (CTD) and per-
formed pulldown followed by hnRNPL immunoblotting (Fig-
ure 7D). We found that hnRNPL binds to the CTD of p53
(Figure 7D). In vitro pulldown assay using Flag-tagged hnRNPL
mutants containing various RRMs and GST-tagged full-length
p53 demonstrated that the first two RRMs of hnRNPL con-
tribute to the binding with p53 (Figure 7E). In summary, the
CTD of p53 interacts with the first two RRMs within hnRNPL
(Figure 7F).
To explore howApela affects the regulation of p53 by hnRNPL,
we performed co-IP experiments in mESCs untreated or treated
with ADR in the absence (shLuc) or in the presence (shApela_1
and shApela_2) of Apela knockdown (Figure 7G). We found
that Apela knockdown increased the interaction between
hnRNPL and p53 after ADR treatment (Figure 7G), indicating
that Apela negatively regulates the interaction between hnRNPL
and p53. This result is consistent with the observation that Apela
and hnRNPL have opposite roles in regulating p53-mediated DIA
of mESCs.eriment using vector only, Apela_WT, and Apela_3UTR in the absence (Ctr) or
; M2, second CA tract disrupted; M12, both CA tracts disrupted).
eriment in the absence (Ctr) or presence of (Adr, 24 hr) ADR treatment.
.s., not significant.
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F
G
Figure 6. hnRNPL Inhibits p53 Activation and p53-Dependent Apoptosis of mESCs
(A) Real-time PCR measuring hnRNPL mRNA levels. Error bars are SEM; n = 3. t test; *p < 0.05; **p < 0.01.
(B) W.B. showing the effect of hnRNPL knockdown on p53.
(C) Immunoprecipitation (IP) followed byW.B. showing the effect of hnRNPL knockdown on p53 K379ac and S18P. Total p53 amount in each lanewas adjusted to
the same level for comparing K379ac and S18P levels.
(D) W.B. showing the effect of hnRNPL knockdown on p53 degradation; 3D view showing the band intensity of p53; lower panel, quantification of p53 levels.
(E) W.B. showing the effect of hnRNPL knockdown on the mitochondrial localization of p53.
(legend continued on next page)
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DISCUSSION
A Tri-Element Negative Feedback Loop that Regulates
p53-mediated DIA in mESCs
The mechanisms underlying DIA of mESCs are not fully appreci-
ated, and the apoptotic role of p53 in mESCs has been still
elusive, which can partially be attributed to the lack of under-
standing of the mechanisms. The discovery of a tri-element
negative feedback loop involving p53, Apela, and hnRNPL con-
tributes to the understanding of DIA of mESCs (Figure 7H). This
tri-element negative feedback loop differs from the well-estab-
lished di-element p53/Mdm2 loop in that it is mediated by a reg-
ulatory RNA, Apela. In addition, this tri-element loop appears to
be cell type specific, consistent with the concept that the regu-
lation of p53 signaling inmESCs is influenced by an ESC-specific
transcriptome.
In mESCs, p53 activity needs to be kept in check because un-
wanted activation of p53 will cause the differentiation and/or
apoptosis of mESCs. Nucleolin and aurora kinase A (Aurka)
inhibit the pro-differentiation activity of p53 in mESCs (Cinghu
et al., 2014; Lee et al., 2012; Montes de Oca Luna et al., 1995).
However, it is unknown which factor or factors suppress the
pro-apoptotic function of p53 in mESCs. The fact that Mdm2
and Mdm4 knockout embryos survive beyond the blastocyst
stage suggests that other factors prevent p53 activation in
mESCs (Jones et al., 1995;Montes deOca Luna et al., 1995; Par-
ant et al., 2001). Here we find that hnRNPL is a factor that antag-
onizes p53-mediated apoptosis in mESCs (Figures 6 and 7).
Thus, multiple proteins are probably needed to subdue p53
activation in mESCs to ensure normal development under un-
stressed conditions. It is worth noting that hnRNPs are multi-
functional proteins (Chaudhury et al., 2010; Ray et al., 2009).
Therefore, the inhibition of p53 activation may only be one of
the functions of hnRNPL. In the same vein, not every transcript
bound by hnRNPL regulates p53 in mESCs (Figure S7C).
Apela binds to hnRNPL and antagonizes its inhibitory effect on
p53 during DNA damage response (DDR). However, the precise
mechanismof this antagonism is currently unknown. It is possible
that Apela antagonizes the activity of hnRNPL by modulating its
conformation or post-translational modifications or competing
with hnRNPL-p53 dimers. Under unstressed conditions, the
copy numbers of Apela and mitochondrial p53 in a single mESCs
are about 110 and 40, respectively. After DNA damage, the copy
numbers of Apela and mitochondrial p53 are about 25 and 160,
respectively (Figures S7D–S7F and Supplemental Information).
These results suggest that the copy number of Apela is enough
to influence the mitochondrial localization of p53, although as
an activator,Apela does not need to release all the p53molecules
to affect apoptosis. In addition, Apelamay regulate many copies
of hnRNPL by a dynamic interaction.
Since Apela positively regulates p53, the repression of Apela
by p53 probably serves as ameans to avoid uncontrolled ‘‘firing’’
of p53. Therefore, our results suggest that mESCs employ this(F) Representative histograms of Annexin V staining of mESCs without (shLuc) and
treatment.
(G) Quantification of (F). Error bars are SEM; n = 3. t test; *p < 0.05; **p < 0.01; n
See also Figure S6.
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needs of suppressing p53 in mESCs without extrinsic DNA dam-
age stress and achieving rapid apoptosis upon DNA damage.
We note that Apela is a modulator, not a determinant, of p53-
mediated DIA of mESCs, and other mechanisms have been
reported. For example, others have shown that the lack of G1/
S arrest in mESCs, mitochondrial priming in human ESCs
(hESCs), and the Golgi localization of Bax also contribute to
the sensitivity of ESCs to DIA (Dumitru et al., 2012; Hong and
Stambrook, 2004; Liu et al., 2013). It is possible that other un-
identified mechanisms exist. Thus, further elucidation of these
mechanisms will help us fully understand the DNA damage
stress response of ESCs.
The Function of Apela in p53-mediated DIA Does Not
Require Its Coding Ability
A striking finding in this study is that the coding ability is dispens-
able for the regulatory function of Apela in p53-mediated DIA of
mESCs. Four lines of evidence support this conclusion. First, the
Aplnr gene that encodes the cognate receptor for the Apela pep-
tide is not expressed in mESCs (Figures 3A and 3B). Second,
Apela without the putative coding region rescues the phenotype
of Apela knockdown (Figures 3D–3F and Figures 5D and 5E),
while the Apela peptide does not (Figure 3G). Third, the region
within Apela that binds hnRNPL is at the 30 UTR (Figure 5).
Fourth, Apela peptide has no effect in DIA of ESCs. It is possible
that Apela has multiple modes of action depending on the
developmental stages: in mESCs, it regulates p53-mediated
apoptosis independent of its coding ability, while during early
development, it controls cell movement through encoded Apela
peptide and the Apela/Aplnr axis. Indeed, Apela and Aplnr
mRNAs are dynamically expressed during early development
using the EB formation model (Figures 3B and 3C). Both Apela
and Apelin are ligands for Aplnr in zebrafish; Apela is expressed
in the early development of zebrafish whileApelin is expressed in
the late development (Chng et al., 2013; Pauli et al., 2014).
Although we detected no activity of Apela peptide in p53-
mediated DIA of mESCs, it is worth noting that our results do
not exclude the possibility that in mESCs Apela is translated
into the Apela peptide, nor do they contradict recent studies
showing that in zebrafish Apela encodes a secretory peptide
(Chng et al., 2013; Pauli et al., 2014). Instead, we identify another
mode of action of Apela: it functions as a regulatory RNA in the
context of p53-mediated DIA of mESCs. A ribosomal profiling
in mESCs suggests that Apela is translated in mESCs (Ingolia
et al., 2011). However, we did not successfully detect the
putative endogenous Apela peptide in mESCs using mass spec-
trometry. In zebrafish, Apela (also called Toddler or ELABELA) is
expressed only at the gastrulation stage whereas Aplnr is ubiq-
uitously expressed (Chng et al., 2013; Pauli et al., 2014). In
mESCs (this study) and hESCs (Chng et al., 2013),Apela is highly
expressed while the receptor gene, Aplnr, is silenced in mESCs.
We speculate that this noncodingmechanism of Apela facilitateswith hnRNPL knockdown in the absence (Ctr) or presence (Adr, 24 hr) of ADR
.s., not significant.
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Figure 7. Apela Inhibits hnRNPL/p53 Interaction
(A) Immunostaining showing the co-localization of hnRNPL and p53 in mESCs untreated or treated with 0.5 mM ADR for 8 hr.
(B) Co-IP using p53 Ab followed by W.B. with hnRNPL Ab.
(C) Co-IP using recombinant hnRNPL and recombinant p53.
(D) Pulldown using purified GST-tagged p53 fragments and mESC lysate.
(E) Co-IP using purified GST-tagged FL p53 and Flag-tagged hnRNPL fragments followed by W.B. with Flag Ab.
(F) Domain structures of p53 and hnRNPL. The dashed black lines indicate the interacting domains within p53 and hnRNPL.
(legend continued on next page)
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a fast DDR of ESCs because it bypasses the step of protein
translation. It remains unclear whether this mode of action of
Apela in mESCs is conserved across all mammals.
In the last several years, many studies have investigated how
regulatory RNAs, especially noncoding RNAs, affect various
cellular processes, such as apoptosis (Hung et al., 2011) and dif-
ferentiation (Klattenhoff et al., 2013). In this study, we serendipi-
touslydiscovered that anRNAspecieswith acodingability,Apela,
has a noncoding function in mESCs, raising the possibility that
other coding RNAs may also have functions beyond their coding
ability. Therefore, our results couldpotentially expand theconcept
of regulatory RNAs and fuel another line of investigation.
EXPERIMENTAL PROCEDURES
ChIP-Seq, RNA-Seq, and Data Analyses
ChIP-seq and data analyses were performed as previously described (Li et al.,
2012). Deep sequencing was done in the Next Generation Sequencing Facility
(NGSF) at the Center for Cancer Research (CCR) in NCI. Briefly, 10 ng of IP
genomic DNA was used in library construction and cluster generation and
was sequenced in the Genome Analyzer IIx (GAIIx) or HiSeq 2000 system.
For RNA-seq, 1 mg of total RNA was sent to the NGSF. All the procedures
were carried out according to Illumina’s protocols. Data analyses and Z-score
algorithm are described in the Supplemental Information.
RPA, RIP, and RIP-Seq
For RPA, we used a protocol described in a previous publication (Huarte et al.,
2010). Briefly, 20 ml M-280 Dynabeads (Life Technologies) was allowed to bind
to 300 ng biotin-labeled sense or anti-sense Apela overnight. The Dynabeads/
RNA complexes were incubated with 400 ml of 2 mg/ml whole-cell lysates at 4C
for 1 hr. Dynabeads were washed three times (5 min each) with RPA buffer
(50 mM Tris [pH 7.5], 250 mM KCl, 5 mM EDTA, 0.5 mM DTT, and 1% NP40
plus protease inhibitors and RNase inhibitors). After washes, beads were
boiled, the supernatant was run on a 4%–12%NuPAGE gel, and silver staining
was performed using the SilverQuest Silver Staining Kit (Life Technologies).
Bands were cut out from the gel and sent for protein identification using
mass spectrometry.
For RIP, 1 mg hnRNPL Ab was incubated with Protein A-Dynabeads over-
night and then incubated with 500 mg total clear lysate in RPA buffer at 4C
for 4 hr. We washed the beads four times with RPA buffer and extracted the
total RNA with Trizol. The concentration was measured and 100 ng RNA
was sent to the NGSF at CCR, NCI. For data processing, we applied a
normalization approach because input and RIP had different averages of
all the FPKMs (fragments per kilobase per million). We made an assumption
that the majority of the RNAs were not bound by hnRNPL. Therefore, we
normalized the FPKM of every transcript to the average of all the
transcripts.
ACCESSION NUMBERS
The accession number for the genomic sequence data reported in this paper is
GEO: GSE65491. Re-analyzed public datasets were described in Table S5.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes seven figures, five tables,
and Supplemental Experimental Procedures and can be found with this article
online at http://dx.doi.org/10.1016/j.stem.2015.04.002.(G) Co-IP showing the effect of Apela knockdown on the interaction between p53
followed by W.B. with hnRNPL, p53, and b-actin Abs.
(H) Left, amodel of a tri-element negative feedback loop formed by p53, Apela, an
Mdm2 shown as a comparison.
See also Figure S7.
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